The introduction of cyclosporine, tacrolimus and infliximab (Remicade, Janssen) has substantially reduced surgery rates in children with acute severe colitis who do not respond to treatment with steroids, Israeli researchers have found.
Before the availability of these agents, colectomy rates in severe disease were 100%, retrospective data show, but they have fallen to about 50% since all three drugs have been available to control disease.
“We show for the first time that the